DEXCOM (UK) LIMITED

Company Registration Number:
09727971 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2024

Period of accounts

Start date: 1 January 2024

End date: 31 December 2024

DEXCOM (UK) LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

DEXCOM (UK) LIMITED

Directors' report period ended 31 December 2024

The directors present their report with the financial statements of the company for the period ended 31 December 2024

Principal activities of the company

The principal activity of the Company in the year under review was as a holding company, whose subsidiaries are engaged in the sale of medical devices directly to patients and customers outside of the United States.

Company policy on disabled employees

The Company gives full consideration to applications for employment from disabled persons where the candidate’s particular aptitudes and abilities are consistent with adequately meeting the requirements of the job. Opportunities are available to disabled employees for training, career development and promotion. Where existing employees become disabled, it is the Company’s policy to provide continuing employment wherever practicable in the same or an alternative position and to provide appropriate training to achieve this aim.



Directors

The directors shown below have held office during the whole of the period from
1 January 2024 to 31 December 2024

Jereme Sylvain
 Michael Jon Brown
 Iskandar Moussa

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
26 September 2025

And signed on behalf of the board by:
Name: Iskandar Moussa
Status: Director

DEXCOM (UK) LIMITED

Profit And Loss Account

for the Period Ended 31 December 2024

2024 2023


£
£
Administrative expenses: ( 1 ) ( 31 )
Operating profit(or loss): (1) (31)
Interest receivable and similar income: 44 1
Profit(or loss) before tax: 43 (30)
Tax: ( 11 ) 7
Profit(or loss) for the financial year: 32 (23)

DEXCOM (UK) LIMITED

Balance sheet

As at 31 December 2024

Notes 2024 2023


£
£
Fixed assets
Investments: 3 725,217 237,938
Total fixed assets: 725,217 237,938
Current assets
Debtors: 4 35 22
Cash at bank and in hand: 15 3
Total current assets: 50 25
Creditors: amounts falling due within one year: 5 ( 255 ) ( 262 )
Net current assets (liabilities): (205) (237)
Total assets less current liabilities: 725,012 237,701
Total net assets (liabilities): 725,012 237,701
Capital and reserves
Called up share capital: 1 1
Share premium account: 556,187 68,908
Other reserves: 169,029 169,029
Profit and loss account: (205 ) (237 )
Total Shareholders' funds: 725,012 237,701

The notes form part of these financial statements

DEXCOM (UK) LIMITED

Balance sheet statements

For the year ending 31 December 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 26 September 2025
and signed on behalf of the board by:

Name: Iskandar Moussa
Status: Director

The notes form part of these financial statements

DEXCOM (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Other accounting policies

    Going concern, foreign currency, Interest Income, Taxation, fixed asset investments, cash and cash equivalents, financial instruments, dividends, accounting judgements

DEXCOM (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 0 0

DEXCOM (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

3. Fixed assets investments note

Fixed asset investments Investment in Subsidiary companies $ Cost or valuation At 1 January 2024 237,938,073 Additions 487,278,666 At 31 December 2024 725,216,739 Net book value At 31 December 2024 725,216,739 At 31 December 2023 237,938,073

DEXCOM (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

4. Debtors

2024 2023
£ £
Other debtors 35 22
Total 35 22

DEXCOM (UK) LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

5. Creditors: amounts falling due within one year note

2024 2023
£ £
Other creditors 255 262
Total 255 262